Alamar Biosciences, Inc. ALMR · Stock Open Alamar Biosciences, Inc. in new tab
Alamar Biosciences, Inc. Analysis (ALMR)
Is Alamar Biosciences, Inc. a good investment? Alamar Biosciences, Inc. (ALMR) is currently trading at 34.85 USD. Market analysts have a consensus price target of 33.40 USD. This suggests the asset is currently trading above analyst expectations.
Investor FAQ
Does Alamar Biosciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Alamar Biosciences, Inc.?
Alamar Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.
Community Discussion